News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase II (World)
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
CASI Pharmaceuticals  (ENMD) To Start China Trial Of Cancer Drug 7/21/2014
Amarantus BioSciences, Inc. Discusses New Independent Peer-Reviewed Research Papers On MANF 7/18/2014
BioTie Therapies Corp. Selects Bracket's CDR System™ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/18/2014
Roche (RHHBY) Alzheimer's Drug Crenezumab Fails Main Goals In Phase 2 Study 7/17/2014
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014
BioTie Therapies Corp. Selects Bracket's CDR System™ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/16/2014
Amarillo Biosciences (AMAR) Announces Positive Analytical Performance Data Poster Presentation For Lympro Test At AAIC 2014 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
Pluristem Therapeutics (PSTI) Initiates South Korean Arm of Multinational Phase 2 Intermittent Claudication Trial 7/8/2014
BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In Lancet Neurology 7/8/2014
Dignity Sciences Release: DS107E-02 - Positive Phase 2 Results In Atopic Dermatitis 7/8/2014
Pharma Two B Ltd. Expands List Of Clinical Sites Enrolling For Phase IIb Study Of P2B001 For PD To 25 7/2/2014
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Report Encouraging Results On Oraxol® For Patients With Advanced Gastric Cancer From A Phase I/II Clinical Study 6/30/2014
TiGenix Announces The Clinical Development Of Cx611 In Early Rheumatoid Arthritis And Severe Sepsis 6/30/2014
Basilea Pharmaceutica (BSLN.SW) Announces Start Of Phase 2a Study With Oncology Drug Candidate BAL101553 6/26/2014
Bone Therapeutics Starts Patient Treatment In First Ever Clinical Trial With Allogeneic Bone Cell Therapy Product 6/25/2014
EnGeneIC Pty Ltd Unveils Clinical Development Strategy for EDV™ Nanocell Technology 6/24/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/23/2014
VBL Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 6/20/2014
Neurim Pharmaceuticals Announces Publication Of Positive Effects Of Add-On Circadin® In Alzheimer's Disease Patients 6/19/2014
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease 6/18/2014
Celsus Therapeutics (CLTX) Receives Approval From The Ministry Of Health Of Israel For Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis Patients 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
Senhwa Biosciences Initiates Phase 1/2 Trial Of CX-4945 In Combination With Gemcitabine And Cisplatin 6/17/2014
Grifols Completes Patient Enrollment In Its Phase2/3 Psoriasis Trial; Final Results Are Expected In Q1 2015 6/17/2014
Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy And Safety In Ground-Breaking Phase II Trigeminal Neuralgia Study 6/16/2014
ALK-Abello A/S’s Partner For Japan Announces Trial Results For House Dust Mite SLIT-Tablet 6/16/2014
Astex Pharmaceuticals (ASTX) Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting 6/16/2014
Generex Biotechnology Corporation (GNBT)/Antigen Express, Inc. (GNBT) Announce Interview Of MD Anderson Cancer Center's Dr. Elizabeth Mittendorf, Principal Investigator On Company's AE37 Phase IIb Breast Cancer Efficacy Trial 6/12/2014
Umecrine Mood's Premenstrual Dysphoric Disorder (PMDD) Drug Fails Phase 2 Study 6/12/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
OphthaliX Inc. Provides An Update On Its Clinical Developments And Strategic Plans 6/9/2014
PsiOxus Therapeutics Limited Announces Positive Study Results Of Oncolytic Vaccine Enadenotucirev At 2014 American Society of Clinical Oncology Annual Meeting 6/3/2014
Jazz Pharmaceuticals plc (JAZZ) Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy 6/3/2014
Novartis AG (NVS)'s Drug Zykadia™ Shrank Tumors In Phase 1 Study 6/3/2014
Can-Fite BioPharma (CFBI) Announces That The FDA Has Agreed With Its Phase 2 Liver Cancer Protocol 6/2/2014
NOXXON Pharma AG’s Emapticap Pegol Study Selected For Late Breaking Clinical Trials Symposium During ERA-EDTA Conference 6/2/2014
D-Pharm Ltd. Reports Completion Of The Second Dose Tier In Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With The Thrombolytic Drug tPA 6/2/2014
BioTie Therapies Corp.: Nepicastat Study In Cocaine Dependence Completes Enrollment Ahead Of Schedule - Top-Line Data Expected Around End 2014 5/27/2014
TRANSGENE (ENX:TNG) Announces Promising Results In An Update From The Phase 2b Part Of TIME Trial With TG4010 In Advanced Non-Small Cell Lung Cancer 5/27/2014
Edison Pharmaceuticals, Inc.'s EPI-743 Granted Orphan Designation For Leigh Syndrome In Japan 5/21/2014
MediWound (MDWD) Initiates Second Phase 2 Clinical Trial Of Escharex™ To Treat Chronic And Other Hard-To-Heal Wounds 5/21/2014
MorphoSys AG's MOR208 Program To Receive Orphan Drug Designation From FDA And European Medicines Agency For The Treatment Of CLL/SLL 5/20/2014
Sanofi Pasteur (SASY.PA) Announces Favorable Phase 2 Study Results For Investigational Clostridium difficile Vaccine At The American Society for Microbiology Meeting 5/19/2014
Juventas Therapeutics, Inc. Data Demonstrates Significant Structural, Clinically Meaningful Benefit In Patients With Advanced Heart Failure 5/19/2014
Pluristem Therapeutics (PSTI) Receives Clearance From South Korea To Use PLX Cells Manufactured At Its New Facility In Its Advances Studies 5/19/2014
Kamada Ltd. (KMDA) Crashes After Key Trial Failure 5/19/2014
Telormedix' Vesimune Successfully Completes Phase 2 For Carcinoma In Situ Of The Bladder 5/16/2014
AstraZeneca PLC (AZN) Touts Success In 2 Phase 2 Studies 5/15/2014
AstraZeneca PLC (AZN) Announces Results Of Phase 2b Studies 5/13/2014
AiCuris And Merck & Co., Inc. (MRK) Announce Publication In New England Journal Of Medicine Of Phase 2 Clinical Trial Results Of Investigational Antiviral Agent Letermovir In Bone Marrow Transplant Patients 5/8/2014
Alcobra (ADHD) Announces FDA Clearance Of Protocol For Phase 2b Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome 5/8/2014
Biota Pharmaceuticals, Inc. Provides An Update On The Development Of Laninamivir Octanoate 5/1/2014
Can-Fite BioPharma (CFBI) Submits Protocol To FDA For Phase II Liver Cancer Study 4/29/2014
Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 In Bladder Cancer 4/28/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients 4/28/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients 4/28/2014
Prima Biomed (PRR.AX)'s CAN-004 Phase 2 Trial For Cvac™ Commences Recruitment 4/28/2014
FDA Approves Commencement Of BrainStorm Cell Therapeutics Inc.'s Phase 2 ALS Clinical Trial In U.S. 4/28/2014
Kamada Ltd. (KMDA.TA) Announces Significantly Improved Infusion Rate For Glassia® 4/24/2014
Teva Pharmaceutical Industries Limited (TEVA) Release: Pride-HD Study Enrolling Patients Globally To Further Evaluate Pridopidine For The Symptomatic Treatment Of Huntington’s Disease 4/24/2014
Anergis Completes Enrolment In The Long-Term Efficacy Trial Of Lead Compound AllerT 4/23/2014
Galapagos NV (GLPG.BR) Release: GSK2586184 Met Primary Endpoint In Phase 2a Psoriasis Study 4/17/2014
Final Data From The Phase 2 COSMOS Study Of Janssen Research & Development's Once-Daily Simeprevir In Combination With Sofosbuvir Presented At The International Liver Congress™ 2014 Of The European Association For The Study Of The Liver (EASL) 4/14/2014
Cytos Biotechnology AG's Asthma Drug CYT003 Flunks Pivotal Phase 2b Study 4/14/2014
GenKyoTex S.A. 's GKT137831 Found To Reverse Fibrosis And Improve Survival In A Model Of Persistent Lung Fibrosis 4/10/2014
Gilead Sciences, Inc. (GILD) Announces Phase 2 Results For Two Investigational All-Oral Sofosbuvir-Based Regimens For The Treatment Of Chronic Hepatitis C 4/10/2014
BioLineRx Ltd. Announces Investigator-Initiated Study For Novel Chronic Myeloid Leukemia Treatment 4/10/2014
Alcobra (ADHD) Submits Protocol To FDA For Phase 2b Clinical Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome 4/10/2014
Adocia Reports Positive Results From Phase 2a Clinical Study Of Ultra-Fast Acting Biochaperone® Lispro 4/9/2014
NOXXON Pharma AG Release: Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin In Subset Of Anemic Patients In Pilot Phase 2a Study 4/8/2014
Mologen AG (MOLGF.PK): DSLIM® Shows Superior Immunoactivation Capabilities 4/8/2014
Viralytics Ltd (VLA.AX) Release: Positive Interim Phase 2 Trial Results For CAVATAK™, Novel Cancer Immunotherapy 4/8/2014
Pfizer Inc. (PFE) Continues Its Streak, Phase 2 Breast Cancer Results Wows Investors And Researchers 4/8/2014
Alnylam Pharmaceuticals (ALNY) Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-Ttrsc, A Subcutaneously Delivered Rnai Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis (ATTR) 4/2/2014
PRANA Biotechnology (PRAN) Tanks As Lead Drug Fails Alzheimer's Study 4/1/2014
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. (RIG2.F) Tout Positive Phase 2b Bipolar Depression Data 3/31/2014
Published Analysis Confirms Positive Results From Auris Medical AG's Phase 2b Study With AM-101 In Treatment Of Acute Inner Ear Tinnitus 3/31/2014
Novartis AG (NVS)'s Rare Lung Cancer Drug Ceritinib Shows Positive Response In Study 3/27/2014
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. (RIG2.F) Shows Off Positive Phase 2b Data For Cariprazine To Treat Depression 3/21/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Recruitment Completed 3/21/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test 3/19/2014
Ipsen (IPN.PA): Dysport Incontinence Treatment Phase 2a Trial Positive 3/18/2014
Pharma Two B Ltd. Commences Phase 2b Study Of Fixed Dose Combination Therapy “P2B001” For Parkinson’s Disease 3/18/2014
Asthma Leader GlaxoSmithKline (GSK) Faces Competition From Roche (RHHBY), AstraZeneca PLC (AZN), Sanofi (France) (SAN.PA), And Teva Pharmaceutical Industries Limited (TEVA) 3/18/2014
Can-Fite BioPharma (CFBI): Phase II Study Protocol To Treat Patients With Advanced Liver Cancer With CF102 Has Been Approved By The IRB In Israel 3/17/2014
Neovacs SA Announces Positive IDSMB Review Of The Phase 2b Study Of TNF-Kinoid In Rheumatoid Arthritis 3/12/2014
ALK-Abello A/S’s Partner For Japan Reports Positive Trial Results For House Dust Mite SLIT-Tablet 3/10/2014
Edison Pharmaceuticals, Inc. Announces Initiation Of EPI-743 Phase 2B/3 Leigh Syndrome Clinical Trial With Dainippon Sumitomo Pharma Co., Ltd. In Japan 3/10/2014
Roche (RHHBY) Drug Cuts Asthma Attacks, Improves Lung Function In Phase 2b Study 3/6/2014
Medivir AB (MVRBF) Release: SVR12 Results From A Phase 2a Study Evaluating Simeprevir And Daclatasvir In Hepatitis C Patients Of Genotype 1 Have Been Presented 3/5/2014
Galapagos NV (GLPG.BR), GlaxoSmithKline (GSK) Anti-Inflammatory Drug Pact Hits A Roadblock 3/4/2014
D-Pharm Ltd. Reports The Successful Interim Analysis Of Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With The Thrombolytic Drug tPA 3/4/2014
Kamada Ltd. (KMDA.TA) Completes Enrollment In U.S. Pivotal Clinical Trial With Kamrab As A Post-Exposure Treatment For Rabies 3/4/2014
Genticel Reaches An Important Milestone By Launching Its Phase II Trial In Women Infected With High-Risk HPV Before The Appearance Of High Grade Cervical Lesions 3/4/2014
Atopix Shows Off Positive Phase 2b Results For Once Daily OC459 In Asthma 3/3/2014
Novartis AG (NVS)'s Experimental Skin Cancer Drug Meets Primary Endpoint In Pivotal Phase 2 Trial 2/21/2014
PRANA Biotechnology (PRAN) Soars As Brain Disorder Drug Succeeds In Phase 2 Trial; Stock Up +39.31% At Market Close (February 18, 2014) 2/19/2014
Galapagos NV (GLPG.BR) Completes Patient Recruitment In Proof Of Concept Study With GLPG0974 In Ulcerative Colitis 2/18/2014
Galapagos NV (GLPG.BR) Completes Patient Recruitment In Proof Of Concept Study With GLPG0974 In Ulcerative Colitis 2/17/2014
Ario Pharma Commences Phase 2a Trial Of TRPV1 Inhibitor For Cough Associated With Chronic Obstructive Pulmonary Disease 2/11/2014
Oramed Pharmaceuticals Inc. (ORMP) Submits Phase 2a Protocol To FDA For The Treatment Of Type 1 Diabetes With Its Oral Insulin Capsule 2/10/2014
AstraZeneca PLC (AZN) Takes On Merck & Co., Inc. (MRK) In Alzheimer's Drug Race 2/7/2014
Can-Fite BioPharma (CFBI) Submitted Phase II Study Protocol With CF102 To Treat Patients With Advanced Liver Cancer 2/6/2014
Targovax TG01 Immunotherapy Reaches Phase 2a In Operable Pancreatic Cancer 2/6/2014
Spinifex Pharmaceuticals ' Phase 2 Results Published In The Lancet Show EMA401 To Be Effective In Reducing Pain In Postherpetic Neuralgia 2/5/2014
Oramed Pharmaceuticals Inc. (ORMP) Announces Successful FDA Phase 2a Clinical Trial Results 1/30/2014
Galapagos NV (GLPG.BR) Release: First Clinical Centers Opened For Phase 2 Crohn's Study With GLPG0634 1/30/2014
Positive Spinal Disc Repair Trial Results Using Mesoblast Limited (MSB.AX) Adult Stem Cells 1/30/2014
Allergy Therapeutics plc: Short Course Immunotherapy Effective In Reducing Ragweed Pollen Allergy 1/27/2014
Prosonix Reports Positive Top-Line Results From Its Phase 2 Clinical Study With PSX1002 In Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) 1/23/2014
BioLineRx Ltd. Receives Orphan Drug Designation For Novel Stem Cell Mobilization Treatment 1/23/2014
D-Pharm Ltd. Completes Recruitment Of Patients Into The First Dosage Tier Of Its Phase 2 Study With THR-18 In Acute Stroke Patients Treated With tPA. 1/21/2014
Prima Biomed (PRR.AX) Revised CAN-004 Trial Of Cvact In Ovarian Cancer Approved In Belgium - First Regulator To Approve Amended CVact Clinical Trial Design 1/20/2014
ERYtech Pharma Announces Clinical Trial Authorizations In Finland And Spain For Its European Phase 2b Study In AML 1/15/2014
D-Pharm Ltd. Announces Recruitment Of The First Patient Into Its Phase 2 Clinical Trial With DP-B99 In Acute High-Risk Pancreatitis 1/14/2014
GlaxoSmithKline (GSK)'s Tafinlar Drug Gets FDA Breakthrough Therapy Designation 1/14/2014
Apogenix' APG101 Demonstrates Significant Prolongation Of Overall Survival In Biomarker-Positive Patients In Phase II Trial For The Treatment Of Recurrent Glioblastoma 1/13/2014
Medivir AB (MVRBF) Release: Interim Results (SVR4) From A Phase 2 All-Oral Combination Study Of Simeprevir And Samatasvir (IDX719) For The Treatment Of Hepatitis C 1/13/2014
EntreMed, Inc. (ENMD) Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA 1/13/2014
Dezima Pharma Completes Patient Enrollment For TULIP Phase 2B Study With CETP Inhibitor TA-8995 1/13/2014
TRANSGENE (ENX:TNG) Announces Topline Preliminary Results From Phase 2b Part Of TIME Trial With TG4010 In Non-Small Cell Lung Cancer 1/9/2014
Positive Feedback From The Scientific Community For Anaconda Pharma's Phase 2a Data For AP611074 First Clinical Proof Of Concept For The Curative Treatment Of Condyloma 1/9/2014
Viralytics Ltd (VLA.AX) Release: Target Enrollment Achieved In CAVATAK™ USA Phase 2 Melanoma Trial With Excellent Interim Results 1/8/2014
Adocia Launches Phase 2a Clinical Trial For Its Ultra-Fast Acting Formulation Of Analog Insulin 1/6/2014
D-Pharm Ltd. Reports Enrollment Of First Patient Into Phase 2 Study Of THR-18 In Stroke Patients Treated With Tissue Plasminogen Activator (tPA) 1/2/2014
Cerenis Therapeutics, Inc.'s Cholesterol Drug CER-001 Fails In Mid-Stage Trial 1/2/2014
Axelar AB's Phase 2 Lung Cancer Study Data Does Not Impress 12/31/2013
Antisense Therapeutics Limited (ANP.AX) Release: Positive Results Achieved From Interim Analysis Of ATL1103 Phase II Trial 12/23/2013
BioSpecifics Technologies Corporation (BSTC) Announces Top-Line Data From Phase 2 Trial Of CCH For Canine Lipoma 12/23/2013
Can-Fite BioPharma (CFBI) Soars On Positive Phase 2 Rheumatoid Arthritis Study; Stock Up +19.23% At Market Close (Dec. 23, 2013) 12/23/2013
GlaxoSmithKline (GSK)'s Malaria Drug Wins FDA "Breakthrough" Status 12/23/2013
Oramed Pharmaceuticals Inc. (ORMP.OB) Announces Successful Results From Ex-US Pharmacokinetic Study Of Its Oral Insulin For The Treatment Of Type 1 Diabetes 12/20/2013
MicuRx Pharmaceuticals Expands Global Clinical Trial Program For Oral Antibiotic MRX-I 12/20/2013
Alcobra (ADHD) Release: FDA Grants Orphan Drug Status To Metadoxine In Fragile X Syndrome 12/19/2013
Octapharma AG Phase 2/3 Trial For The Targeted Treatment Of Relapsing Multiple Sclerosis Enrols First Patients 12/18/2013
NovaBiotics Ltd Initiates Development Of Orphan Drug In Cystic Fibrosis 12/17/2013
Biomay AG Successfully Completes Interim Analysis Of Phase 2 Study With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32 12/16/2013
Alcobra (ADHD) Announces Highly Statistically Significant Positive Phase 2b Clinical Trial Results In Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder 12/16/2013
BioLineRx Ltd. Announces Promising Initial Phase 2 Results Of Acute Myeloid Leukemia Treatment 12/16/2013
Medivir AB (MVRBF) Release: An All-Oral Phase 2a Study Combining Simeprevir, TMC647055 And JNJ56914845 In Hepatitis C Patients To Be Initiated 12/12/2013
Targeted Antibody, Immune Checkpoint Blocker Rein In Follicular Lymphoma 12/12/2013
Kamada Ltd. (KMDA.TA) Announces Completion Of Pivotal Phase 2/3 Clinical Trial In Europe And Canada Of Inhaled AAT To Treat Alpha-1 Antitrypsin Deficiency 12/11/2013
Preliminary Findings Of BrainStorm Cell Therapeutics Inc.'s Phase 2a Study Reported As "Extremely Optimistic" 12/10/2013
NOXXON Pharma AG Release: Interim Phase 2a Results For Spiegelmer® Olaptesed Pegol (NOX-A12) In CLL And MM Studies 12/9/2013
NOXXON Pharma AG Release: Interim Phase IIa Results For Spiegelmer Olaptesed Pegol (NOX-A12) In CLL And MM Studies 12/9/2013
Neovacs SA Succesfully Enrolls First Patients In Its Phase 2b Study Of Tnf-Kinoid For The Treatment Of Rheumatoid Arthritis 12/9/2013
Can-Fite BioPharma (CFBI) Anticipates Results From Two Clinical Trials 12/5/2013
Apogenix' APG350 Effectively Induces Apoptosis Of Tumor Cells Via TRAIL Pathway Independent Of Fc-gamma Cross-Linking 12/5/2013
Mesoblast Limited (MSB.AX) Reports Positive Type 2 Diabetes Trial Results 12/4/2013
InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used In Combination With Standard Antiretroviral Therapy In Treatment Of HIV-Infection 12/2/2013
Galapagos NV (GLPG.BR) Announces GSK2586184 JAK1 Molecule Moves Into Phase 2 For Ulcerative Colitis 11/27/2013
Bone Therapeutics Treats First Patients In PREOB® Pivotal Phase IIb/III Trial For The Treatment Of Non-Union Fractures 11/26/2013
BioLineRx Ltd. Announces New Positive Results In Phase 2a Trial For Orally Available Inflammatory Bowel Disease Treatment 11/26/2013
Alcobra (ADHD) Announces New Findings On Diminished Abuse Potential Of Its Proprietary Drug Candidate, MG01CI 11/22/2013
Zealand Pharma  (ZEAL.CO) Advances Danegaptide, Its Novel Drug Candidate, Into A Phase 2 Clinical Proof-Of-Concept Study For Protection Against Reperfusion Injury In Patients With Myocardial Infarction 11/20/2013
Pluristem Therapeutics (PSTI) Receives Regulatory Approval To Extend Its Phase II Study of PLX-PAD Cells In The Treatment Of Intermittent Claudication To South Korea 11/13/2013
PsiOxus Therapeutics Limited Cancer-Wasting Drug Better Than Placebo In Phase 2 Study 11/13/2013
Revalesio Initiates Phase IIa Study of RNS60 in Multiple Sclerosis at University Hospital Zurich 11/11/2013
ERYtech Pharma Announces Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia 11/11/2013
GenKyoTex S.A. NOX Inhibitor GKT137831 Successfully Shown To Halt Diabetic Kidney Disease 11/11/2013
Amakem NV to Present Top-Line Clinical Results for its Lead Candidate, AMA0076, at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Meeting 2013 11/7/2013
Shanghai Sundise Reports Positive Results From TCM Liver Fibrosis Trial 11/7/2013
Trophos Completes Pivotal Phase II/III Study of Olesoxime in Spinal Muscular Atrophy (SMA) 11/6/2013
Medivir AB (MVRBF) Release: Results From the COSMOS Study With Simeprevir and Sofosbuvir in Cirrhotic and Non-Cirrhotic HCV genotype 1 Patients Presented at American Association for Study of Liver Diseases 11/5/2013
AB Science (AB.PA) Release: Masitinib is Being Investigated in the Treatment of Amyotrophic Lateral Sclerosis (ALS) 11/5/2013
Serodus AS Enrolls First Patient in SER100 Phase 2a Isolated Systolic Hypertension Clinical Study 11/5/2013
Active Biotech AB (BTPC)'s Partner Teva Pharmaceutical Industries Limited (TEVA) Initiates a Further Clinical Trial in Multiple Sclerosis 11/4/2013
Alfact Innovation Announces Positive Clinical Trial Results for Treatment of AIH- and HBV- Related Acute-on-Chronic Liver Diseases 11/4/2013
GeNeuro Successfully Completes Phase 2a Clinical Study With Novel Approach to Treat Multiple Sclerosis 11/4/2013
Immunocore Limited Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma 10/31/2013
PRANA Biotechnology (PRAN)'s PBT2 Reverses Memory Loss in Normal Aging 10/31/2013
Anaconda Pharma: Scientific Breakthrough in HPV Treatment 10/31/2013
e-Therapeutics plc Starts Phase IIb Trial of ETS6103 in Major Depressive Disorder 10/31/2013
Addex Therapeutics (ADXN.SW) Licensee Completes Enrollment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 10/29/2013
Alexion Pharmaceuticals Inc. (ALXN) Scores Another Breakthrough Designation for Ultra-Rare Metabolic Disorder 10/29/2013
GENFIT Corp. (ALGFT) Release: GFT505: the DSMB Approves the Continuation of the Phase 2b Study in NASH 10/28/2013
National Institutes of Health (NIH)-Sponsored Consortium of Food Allergy Research (CoFAR) Starts a Phase 2 Clinical Study With DBV Technologies' Viaskin® Peanut in the Treatment of Peanut Allergy 10/24/2013
Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis' Birch Pollen Allergy Vaccine AllerT 10/21/2013
GANYMED Pharmaceuticals AG's IMAB362 Receives Orphan Drug Designation From FDA and European Medicines Agency for Pancreatic Cancer 10/21/2013
D-Pharm Ltd. Commences Phase 2 Study With THR-18 in Stroke Patients Treated With Tissue Plasminogen Activator (tPA) 10/16/2013
Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) Announces Positive Results From Its Phase 2 Clinical Study of E-58425 in Acute Pain 10/16/2013
PledPharma Release: The Sixth Patient in the First Part of the PLIANT-Study Approved for Continued Dosing 10/15/2013
Acacia Pharma Announces Positive Phase 2 Results With APD515 for Xerostomia in Advanced Cancer 10/15/2013
Genmab A/S (GEN.CO) Touts Positive Phase 2 Results for Multiple Sclerosis Drug 10/14/2013
Alkermes plc (ALKS) Announces Alignment With FDA on Plans for Pivotal Program for ALKS 5461 for Major Depressive Disorder 10/9/2013
Kiadis Pharma Secures Manufacturing Services Agreement for Its Phase II Clinical Program With Blood Cancer Treatment ATIR™ With the German Red Cross Blood Donor Service 10/7/2013
New Data Show Novartis AG (NVS)' Gilenya® Reduced Brain Volume Loss in MS Patients 10/7/2013
Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte Corporation (INCY)'s Oral JAK1 Inhibitor in Patients With Chronic Plaque Psoriasis 10/3/2013
Pluristem Therapeutics (PSTI) Receives Israeli Ministry of Health Approval to Expand Its Phase 2 Clinical Trial in Intermittent Claudication to Israel 10/2/2013
MorphoSys AG Collaborator to Start Pivotal Study With Bimagrumab 10/2/2013
Trophos Announces Final Patient Completion of Phase II Proof-of-Concept Study of TRO40303 in Patients Treated for Acute Myocardial Infarction 10/2/2013
Circassia Limited's Grass Allergy Treatment Achieves Significant Symptom Reduction During Hay Fever Season 10/1/2013
Prima Biomed (PRR.AX) Management Presentation of CVAC™ Phase 2 Trial Results 10/1/2013
BrainStorm Cell Therapeutics Inc. Launches US Activities for Its Multi-Center ALS Clinical Trial 10/1/2013



//-->